INTRODUCTION
Glioma, the most common primary brain tumor, has aggressive and highly invasive characteristics and is a leading cause of cancer-related death by central nervous system tumors. 1 Despite the development of treatment options, including surgery, chemotherapy and radiotherapy, the median survival time of patients with these tumors is about 1 year after diagnosis. 2 The major limitations of glioma treatment are the prevalence of recurrence after surgery, infiltration into surrounding tissues and intrinsic or acquired resistance to chemo-and radiotherapy. 3 Intrinsic resistance to chemo-and radiotherapy is highly reminiscent of the recently emerging cancer stem-like cell theory, which holds that the cells with potent tumorigenic capacity are the same as those that contribute to tumor maintenance and recurrence. 3 Cancer stem-like cells (CSCs), also called tumor-initiating cells, are a small population of tumor cells that self-renew like normal stem cells and are capable of inducing tumorigenesis. CSCs were first recognized in leukemia. 4 The existence of CSCs was then identified in solid tumors such as brain, 5 breast, 6 colon, 7 lung 8 and other tissues. 9 Notably, several independent reports have demonstrated the existence of brain tumor stem-like cells in different patient tissues. 5,10 --13 These cells are thought to be responsible for resistance to chemo-and radiotherapy, induction of tumor angiogenesis and tumorigenic capacity under hypoxic conditions. 14 --17 For this reason, CSCs are regarded as good potential therapeutic targets; however, critical molecular mechanisms that maintain the 'stemness' of CSCs are largely unknown.
c-Jun N-terminal kinase (JNK) is a member of the mitogenactivated protein kinase superfamily, together with extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase. The JNK family consists of three isoforms, JNK1, JNK2 and JNK3, which are activated by various stress stimuli, including UV-irradiation, reactive oxygen species and cytokines. 18 Activated JNK translocates into the nucleus and activates transcription factors such as c-Jun, JunB, JunD and ATF2. Although its major physiological function is to induce apoptosis, JNK also regulates cellular proliferation and differentiation. 19 Notably, JNK is constitutively activated in primary glial tumors and its activation is critically correlated with histological grade and epidermal growth factor receptor (EGFR) expression in diffuse gliomas. 20, 21 In addition, JNK activation has been shown to have a crucial role in the tumorigenesis of gliomas, possibly through EGFR-mediated signaling pathways. 22, 23 However, the role of JNK in maintaining stemness of glioma cells remains unknown.
Notch, Wnt and Sonic hedgehog, signaling pathways for development, are known to have important roles in maintaining stemness in the stem cell niche. 24 Notch is critically involved in the regulation of self-renewal and expansion of many different types of normal stem cells, including neural stem cells. 25 Activation of Notch pathway is initiated by binding of Notch ligands (Delta-like 1, 2 and 4; and Jagged-1 and -2) in one cell to Notch receptors (Notch 1--4) of a neighboring cell. Upon ligand binding, the Notch receptor is proteolytically cleaved, resulting in the release of the notch intracellular domain, which ultimately translocates into the nucleus and activates Notch-dependent transcriptional events. 25 Aberrant Notch activation has been found in various malignant tumors, including breast cancer, leukemia and glioma. 26 In brain tumor, especially, Notch signaling is highly activated in high-grade primary gliomas, compared with low-grade astrocytomas, as evidenced by elevated expression of Hes-1, a well-known transcriptional target of Notch signaling. 27 In addition, ligand of Numb protein X, which is implicated in the degradation of the Notch signaling antagonist Numb, is reported to be downregulated in glioma, leading to activation of Notch signaling. 28 Notch activation through introduction of the notch intracellular domain stimulates growth and sphere formation in glioma cell lines and endows radioresistance to CD133 þ glioma stem cells. 29, 30 In contrast, Notch inhibition by small interference RNAs (siRNAs) or treatment with g-secretase inhibitors induces cell death and differentiation of glioma cell lines, depletes CD133
þ cell population and suppresses intracranial tumor formation of glioma stem-like cells. 31 --33 In this study, we attempted to identify specific signaling pathways involved in the maintenance of stem-like properties in glioma cells. We found that the JNK signaling pathway has a critical role in self-renewing and tumorigenic abilities of stem-like cells in glioma cell lines, as well as patient-derived glioma cells. Notably, our findings suggest that JNK upregulates Notch-2 expression, at least via c-Jun, and thereby maintain stemness of glioma stem-like cells. JNK signaling pathways may be a novel target for eliminating stem-like cancer cells in gliomas.
RESULTS

Inhibition
of JNK signaling suppresses self-renewal and enhances differentiation in glioma stem-like cells Glioma subpopulation expressing CD133 is enriched in cancer stem-like cells and shows greater tumorigenic potential than CD133-negative cells. 5 In a similar way to neural precursor cell culture, those glioma stem-like cells expressing CD133 can be enriched in serum-free medium supplemented with growth factors, in which a fraction of glioma cells continue to proliferate and form spheres instead of monolayer. 10, 29 Here, we also cultured U87 and U373 glioma cells in sphere forming conditions (Supplementary Figure S1A) as described before 34, 35 and found the increase of CD133, Nestin-expressing cells, compared with monolayer-cultured cells (Figure 1b and Supplementary Figure S1B ). Sphere-cultured glioma cells also enhanced mRNA and protein expression of neural stem cell markers such as CD133, Nestin and Musashi-1, compared with monolayer-cultured glioma cells (Supplementary Figure S1B) . These results are consistent with previous studies that glioma cell lines contain a subset of glioma stem-like cells that can be enriched under serum-free, sphereforming culture conditions. 33, 36 To investigate the possible role of specific kinases in stemness of glioma cells, we first examined the activation status of mitogenactivated protein kinases in sphere-cultured glioma cells. Spherecultured glioma cells exhibited enhanced phosphorylation of ERK1/2 and JNK1/2, but not p38 (Figure 1a) . Glioma stem-like cells were also enriched even in serum-free medium without supplementation of EGF and basic fibroblast growth factor (bFGF) forming spheres (Supplementary Figure S2A) and expressed higher levels of stem cell markers such as Nestin, Musashi-1 and CD133 (Supplementary Figure S2B) , compared with monolayercultured cells. Notably, these sphere-forming cells cultured in serum-free medium without EGF and bFGF also showed the increased activity of JNK1/2 compared with monolayer-cultured cells (data not shown), indicating that JNK1/2 activation is not simply caused by supplementation of EGF and bFGF.
We next treated sphere-cultured cells with pharmacological inhibitors of ERK1/2 (U0126), p38 (PD169316) or JNK (SP600125) to determine whether inhibition of these kinases affects stemness of glioma cells. Fluorescence-activated cell sorting (FACS) analysis showed that inhibition of JNK, but not ERK1/2 and P38, significantly reduced the CD133 þ /Nestin þ cell population both in sphere-cultured glioma cell lines, U87 and U373 (Figure 1b) . Moreover, inhibition of JNK suppressed the expression of Nestin and Musashi-1 in sphere-cultured glioma cells, whereas inhibition of ERK1/2 or p38 did not (Figure 1c ). Immunocytochemistry analysis confirmed that treatment with inhibitor of JNK, SP600125 suppressed Nestin and Musashi-1 expression, and further showed that JNK inhibition upregulated the expression of Tuj1, a neuronal differentiation marker (Figure 1d ). We next examined the effect of JNK on sphere-forming ability and soft-agar clonogenicity, which are surrogate assay methods for evaluating stemness of stem-like cancer cells in vitro. As expected, pharmacological inhibition of JNK dramatically suppressed sphere formation ( Figure 2a ) and colony formation in soft agar ( Figure 2b ) in both glioma cell lines, U87 and U373. In contrast, treatment with U0126, inhibitor of ERK1/2 and PD169316, inhibitor of p38 had only a marginal effect on sphere formation (Supplementary Figure S3A) and colony formation in soft agar (Supplementary Figure S3B) . Taken together, these results suggest that inhibition of JNK signaling suppresses self-renewal of glioma stem-like cells, whereas ERK1/2 and p38 is not involved in stemness.
JNK has a central role in the maintenance of self-renewal in glioma stem-like cells To further verify the involvement of JNK in regulating stemness of glioma cells, we next investigated the specific role of JNK in these events using siRNAs targeting of JNK isoforms. Treatment with siRNA targeted to JNK1 and JNK2 significantly suppressed sphere formation in U87 and U373 glioma cells (Figure 3a) . Moreover, clone-forming ability at a single cell level was markedly inhibited by treatment with siRNA targeted to JNK1 and JNK2 (Figure 3b ). Only 24 of 96 cells (25%) formed clones by downregulation of JNK1, and 21 of 96 cells (22%) by downregulation of JNK2, whereas 85 of 96 cells (88.5%) formed clones in glioma cells treated with control siRNA. Similarly to treatment with JNK inhibitor, siRNA-mediated downregulation of JNK decreased cell surface expression of CD133 in sphere-forming glioma cells ( Figure 3c ). As siRNA targeted to JNK2 was more effective than targeted to JNK1 in reducing sphere formation and CD133 expression, we focused on JNK2 in further study. Treatment of sphere-forming glioma cells with siRNA targeted to JNK2 suppressed stemness-related genes such as Notch-2, Sox2 and b-catenin (Figure 3d ). However, Notch-1 and Gli1 was not altered. Inhibition of JNK activity with SP600125 also suppressed the expression of these genes at both protein and mRNA levels, though Notch-1, Gli1 and Sonic hedgehog were not altered (Supplementary Figures S4A and C) . Notably, expression of Notch-2, but not Notch-1, -3 or -4, was enhanced in sphere-cultured cells compared with monolayer-cultured glioma cells, and this increase was suppressed by JNK inhibition (Supplementary Figure S4B) . In addition, inhibition of JNK also decreased mRNA levels of b-catenin in sphere-forming glioma cells (Supplementary Figure  S4D) . Taken together, these data indicate that JNK signaling is required for expression of genes related with stemness, suggesting that JNK is critical for the maintenance of stemness in spherecultured glioma cells.
PI3K is an upstream kinase of JNK that governs the self-renewal of glioma stem-like cells As phosphoinoside 3-kinase (PI3K)/Akt pathway has been shown to regulate glioma stemness, 37 we investigated whether this pathway is linked to JNK signaling in the maintenance of stemness of glioma cells. As expected, sphere-forming glioma cells showed significantly higher levels of lipid phosphatase activity and phosphorylated Akt compared with monolayer-cultured glioma cells (Supplementary Figure S5) . Treatment with PI3K-specific inhibitor LY294002 strongly reduced CD133 þ /Nestin þ cell population ( Figure 4a ) and suppressed colony formation ( Figure 4b ) in U87 and U373 sphere-forming glioma cells. Consistent with these results, treatment with siRNA targeted to Akt also attenuated the increase in the CD133 þ /Nestin þ cell population of sphere-forming glioma cells (Figure 4c) . To investigate the possible relationship between PI3K/Akt and JNK pathways in controlling stemness in glioma cells, we treated sphere-forming glioma cells with LY294002 and SP600125, inhibitors of PI3K and JNK, respectively, and investigated the phosphorylation status of JNK and Akt. Notably, treatment with inhibitor of PI3K, LY294002 strongly reduced phosphorylated JNK levels, suppressed expression of Musashi-1 and Nestin, and reduced the lipid phosphorylation activity of the p85 subunit of PI3K ( Figure 5a ). In contrast, treatment with inhibitor of JNK, SP600125 did not affect the lipid phosphorylation activity of p85 or Akt phosphorylation (Figure 5b ). Vice versa, treatment with siRNA targeted to Akt did not block JNK phosphorylation in sphere-forming glioma cells (Figure 5c ). Taken together, these data suggest that PI3K is an upstream kinase of JNK, independently from Akt signaling, and that PI3K/JNK and PI3K/Akt pathways may have crucial independent roles in the maintenance of glioma stem-like cell population.
siRNA-mediated knockdown of JNK sensitizes sphere-forming glioma cells to irradiation and anti-cancer drugs As stem-like cancer cells are reported to endow resistance to chemo-and radiotherapy, 38, 39 we examined whether inhibition of JNK signaling increases the sensitivity of sphere-forming glioma cells to chemotherapeutic drugs and ionizing radiation (IR). Single treatment of sphere-forming glioma cells with etoposide or IR (10 Gy) or siRNA targeted to JNK2 had only a marginal effect on cell death compared with untreated controls ( Figure 6 ). However, pretreatment with siRNA targeting of JNK2 markedly sensitized sphere-forming glioma cells to etoposide and IR (10 Gy; Figure 6 ). These results suggest that JNK signaling would contribute to resistance of sphere-forming glioma cells to anti-cancer drug and radiation.
JNK regulates glioma stem-like cell population in patient-derived glioma cells In this study, downregulation of JNK in glioma cell lines led to a decrease of stemness-related genes such as Nestin, CD133, Musashi-1, Sox2 and Notch-2 without causing cell death. Corresponding to these results, downregulation of JNK signaling also decreased characteristics of stemness such as self-renewal and tumorigenic ability. To further address the clinical relevance of JNK signaling targeting of stem-like cells in glioma patients, we attempted to extend our observation to patient-derived glioma cells (X01GB, X02GB and X03AOA). To this end, glioma stem-like cells were sorted from each patient-derived glioma cells, based on their expression of CD133, known stem-cell marker in glioma (Bao et al. 15 ), by a magnetic-activated cell sorting using CD133 antibody-conjugated magnetic beads (Figures 7a--c) . The sorted cells were then analyzed by immunocytochemistry, FACS and immunobloting. Notably, CD133-positive cells had more phosphorylated form of JNK1/2 and expressed more Notch-2, compared with CD133-negative cell population within patientderived glioma cells (Figure 7c) . Moreover, consistent with the results of glioma cell lines, siRNA-mediated downregulation of JNK2 also led to a decrease of Notch-2 expression in patientderived glioma cells (Figure 7d ). In addition, pharmacological inhibition of JNK, but not ERK1/2 and P38, significantly reduced the CD133 þ /Nestin þ cell population in patient-derived glioma stem-like cells (Supplementary Figure S6) . 40 As JNK signaling is known to be transduced by phosphorylation of c-Jun, a transcription factor, we next investigated whether JNK suppresses Notch-2 expression via c-Jun. By semi-quantitative reverse-transcription PCR, we observed that downregulation of c-Jun decreases Notch-2 expression (Figure 7e ), suggesting that JNK-mediated Notch-2 expression is regulated at least via c-Jun. However, c-Jun may not be the unique molecule by which JNK regulates Notch-2, because downregulation of JNK led to more decrease of Notch-2 expression, compared with downregulation of c-Jun (data not shown). Taken together, these results suggest that JNK2, similarly to glioma cell lines, is also an important regulator of glioma stem-like cells in patient-derived glioma cells.
JNK targeting suppresses intracranial tumor formation by glioma cells in vivo Finally, we tested the effect of JNK on intracranial tumor formation by glioma cells in vivo. To this end, small hairpin RNAs (shRNAs) targeted to JNK2 was introduced to U87 glioma cells by lentivirusmediated gene delivery system. Transduction with shRNA targeting of JNK2 greatly decreased clone-forming ability of U87 and U373 sphere-forming glioma cells (Supplementary Figure S7A) , soft-agar colony-forming activity (Supplementary Figure S7B) , compared with scrambled shRNA-transduced cells. Also, downregulation of JNK2 led to a decrease of cell surface expression of Figure S7C) and expression of stemnessrelated genes such as Notch-2, Sox2 and b-catenin (Supplementary Figure S7D) . To examine the effect of JNK2 on tumor formation in vivo, U87 sphere-forming glioma cells were transduced with JNK2 shRNAs or scrambled shRNAs, and injected to brain of athymic mice. Notably, intracranial tumor formation was markedly suppressed 15 days after transplantation of JNK2 shRNAtransduced U87 sphere-forming glioma cells to brain of athymic nude mice, compared with scrambled shRNA-transduced cells (Figure 8 ). Taken together, these data suggest that inhibition of JNK pathway could target glioma stem-like cells and would be a good therapeutic strategy for treatment of glioma.
CD133 (Supplementary
DISCUSSION
It has been suggested that the major underlying factor in the poor prognosis of glioblastoma patients, despite drastic intervention strategies like chemo-and radiotherapy, is the presence of stemlike cancer cells. Accordingly, identifying the molecular pathways that maintain stemness in glioma cells would provide potential targets for therapeutic strategies designed to eliminate glioma stem-like cells and could prove to be a promising approach for improving the outcome of therapies deployed against this malignant disease. In this study, we sought to identify the regulatory mechanisms that are critical in maintaining stemness of glioma cells. We found that the JNK pathway is crucially involved in maintenance of stemness in glioma cells. Pharmacological inhibition of the JNK pathway or siRNA-mediated JNK1/2 knockdown significantly decreased the size of the CD133 þ /Nestin þ cell population, suppressed sphere formation and soft-agar colony formation, and reduced the expression of neural stem cell-related genes such as Nestin, CD133, Musashi-1, Sox2 and Notch-2, which were upregulated under sphere culture conditions of glioma cells.
Moreover, we found that PI3K is an upstream kinase of JNK pathway-mediated self-renewal and tumorigenecity. Previous studies have shown that the PI3K/Akt pathway is important for the maintenance of cancer stem-like cells in breast cancer, 41 prostate cancer, 42 medulloblastoma 43 and glioma. 37 In line with these previous observations, our data also demonstrate that the PI3K pathway is critical for stemness of glioma cells. PI3K activity was high in sphere-cultured glioma cells, and inhibition of PI3K activity with LY294002 suppressed the expression of stem cell markers. Intriguingly, inhibition of PI3K activity with LY294002 decreased the phosphorylated form of JNK, whereas treatment with siRNAs targeting of JNK had no effect on PI3K activity. In addition, treatment with siRNA targeted to Akt had no effect on JNK phosphorylation. These results suggest that both PI3K/JNK and PI3K/Akt signaling pathways are important for the maintenance of self-renewal and tumorigenic capacity of glioma stemlike cells, however, independently from each other.
Although JNK signaling regulates a variety of cellular events such as proliferation and differentiation, its major physiological function is to induce apoptosis. 19 JNK signaling-induced apoptosis was previously reported in rat neural stem cells. 44 Thus, in normal brain, activation of JNK signaling appears to induce apoptosis of neural stem cells. In contrast, JNK has been reported to be constitutively activated in malignant gliomas. 20 --22 Immunohistochemical analyses of glioma tissues showed that constitutive activation of JNK is strongly correlated with EGFR expression and the histological grade of malignant gliomas (Li et al. 21 ). JNK, especially JNK2, has an essential role in regulating the growth of T98G glioma cells by suppressing p21
Cip1/Waf1 expression under non-stress conditions. 45 JNK2 expression was also detected in 86% of human brain tumor tissues and was reported to be responsible for the tumorigenicity of glioma cells, possibly through Akt activation and eIF4E overexpression. 20, 23 Thus, in contrast to normal neural stem cells, JNK signaling does not induce cellular apoptosis in glioma stem-like cells; rather has a critical role in the maintenance of stemness in malignant glioma cells. Though it remains unknown, we assume that malignant glioma cells may be clonally selected during brain tumor progression and escaped JNK-mediated apoptotic pathways. Indeed, the ratio of JNK to Nestin, a stem cell marker, in glioma tissues is linked to patient prognosis, 46 suggesting a role for JNK in glioma stemness. Also, our study clearly implicates the JNK pathway in selfrenewal and tumorigenicity of glioma cells. The phosphorylated (active) form of JNK was enriched in sphere-cultured U87 and U373 glioma cells, as well as CD133-positive cells sorted from patient-derived glioma cells. Notably, pharmacological inhibition or knockdown of JNK1 or JNK2 by siRNA led to suppression of sphere formation, clonogenicity and stem cell marker expression in sphere-cultured glioma cells, indicating that the JNK signaling pathway has a critical role in the maintenance of malignant glioma stem-like cell population.
Intriguingly, in our study, activation of the JNK pathway was specifically linked to augmentation of Notch-2 expression, which appeared to be responsible for maintaining stemness of glioma cells. In previous studies, Notch expression is correlated with glioma grade. 27 Low-grade astrocytomas and secondary glioblastomas are characterized by inactive Notch signaling, whereas Notch signaling is activated in primary glioblastomas. Notch-1 and its ligands, Delta-like 1 and jagged-1 are overexpressed in glioma cell lines and tissues, and inhibition of them results in an increase of cell death, a decrease of cell proliferation and invasion, and promotion of differentiation, together with upregulation of glial fibrillary acidic protein and downregulation of vimentin expression. 32, 47 Notch signaling is also critical for maintaining stemness of brain tumor stem-like cells. Inhibition of Notch pathway exhausts CD133 þ stem-like tumor cells and suppresses sphere formation in vitro and tumor formation in vivo. 29, 33, 48 Furthermore, Notch signaling pathway directly upregulates the stem cell marker Nestin in glioma. 49 Consistent with these previous studies, our findings show that Notch-2 expression is upregulated in spherecultured cells, compared with monolayer-cultured cells. Moreover, the isolated patient-derived glioma stem-like cells based on expression of CD133 displayed higher expression levels of Notch-2, compared with counterpart, CD133-negative cell population. Notably, Notch-2 expression was decreased by inhibition of JNK activity, suggesting that JNK signaling acts through Notch-2 pathways to maintain self-renewal of glioma stem-like cell population. Moreover, targeting the JNK pathway with shRNA strongly suppressed intracranial tumor formation in mouse brain, implicating its clinical relevance.
However, Notch signaling pathway also has a pivotal role in maintaining normal embryonic neural stem cell pool. 50, 51 Notch signals are expressed in neural stem and progenitor cells residing in the subventricular zone, a perivascular region in adult rodent brain, where endogenous neural stem cell population is tightly regulated by a variety of factors including Notch signaling. 52 In a similar way, glioma stem-like cells are localized in a perivascular region, in which Notch signaling is triggered by binding of transmembrane ligands on endothelial cells to Notch receptors on glioma cells. 53 However, Notch signaling in glioma stem-like cells in their niche also appears to be regulated by other distinctive mechanisms. Recently, Eyler et al. 54 found that proliferation of glioma stem-like cells is facilitated by nitrogen oxide (NO), whereas the increase of NO had no effect on cell growth of normal neural stem cells. The role of NO in facilitating glioma cell growth was further supported by Charles et al., 55 in which they found that NO activates Notch signaling and promotes glioma stem-like cell population in vivo. In our study, we found that Notch signaling is activated by JNK signaling. Previously, it was also reported that JNK signaling is activated by NO. 56 Thus, NO synthesis in glioma cells may activate JNK and sequentially cause activation of Notch signaling, thereby leading to expansion of glioma stem-like cell population. However, in endogenous neural stem cells, Notch signaling may not be regulated by JNK, because JNK signaling appears to induce apoptosis in normal neural stem cells. 19, 44 In addition, cellular proliferation of normal neural stem cells was not affected by the increase of NO levels, whereas NO led to the increase of glioma stem-like cell population. 54 Thus, the route of Notch signaling activation, NO/JNK/Notch may be distinctive pathway for the maintenance of glioma stem-like cells, implicating a novel therapeutic target for glioma stem-like cells without damaging endogenous neural stem cells. Converging our findings to previous studies, we summarized schematically the route of Notch signaling activation in glioma in Figure 8b .
In conclusion, our findings suggest that glioma cells maintain stem-like cell population via both PI3K/JNK and PI3K/Akt signaling pathways. JNK signaling is a critical pathway for self-renewal of glioma stem-like cell population, and likely acts through regulation of Notch-2 expression. These findings may provide a new therapeutic target for glioma stem-like cells.
MATERIALS AND METHODS
Chemical reagents and antibodies
Polyclonal antibodies to phospho-Akt(Ser473), phospho-Akt(Thr308), phospho-ERK1/2(Thr202/Tyr204), phospho-p38(Thr180/tyr182), ERK1/2, p38 and phospho-JNK1/2(Thr183/tyr185) were obtained from Cell Signaling Technology (Beverly, MA, USA). Polyclonal antibody to CD133 was obtained from Abcam (Seoul, Korea) and polyclonal antibodies to Nestin, Musashi-1 and Notch-2 were purchased from Millipore (Billerica, MA, USA). Polyclonal antibodies to Akt and JNK2 were purchased from Santa Cruz (Santa Cruz, CA, USA). And 4, 6-diamidino-2-phenylindole, EGF and monoclonal antibodies to b-actin were obtained from Sigma (St Louis, MO, USA). Basic fibroblast growth factor (bFGF) was purchased from R&D Systems (Seongnam, Korea). Anti-mouse Alexa Fluor 488, anti-rabbit Alexa Fluor 488 and B27 were purchased from Invitrogen (Seoul, Korea). CD133 (directly conjugated with phycoerythrin, clone 293C3) and mIgG2b-PE were purchased from Miltenyi Biotech Ltd (San Diego, CA, USA). Inhibitors specific to JNK (SP600125), p38 mitogen-activated protein kinase (PD169316), MEK (U0126), PI3K (LY294002) and Etoposide (VP16) were obtained from Calbiochem (San Diego, CA, USA).
Cell and spheres culture U87MG and U373MG (glioma cancer cells) were obtained from the Korean Cell Line Bank (Seoul, Korea) and cultured in the recommended medium containing 10% fetal bovine serum, and in this medium condition, glioma cells were grown in monolayer. Patient-derived glioma stem-like cells X01GB, X02GB and X03AOA were established from acutely resected human tumor tissues. 40, 57 The X01GB line was derived from a 68-year-old woman with a glioblastoma multiforme. The X02GB line originated from a man with glioblastoma multiforme. The X03AOA was derived from a woman with anaplastic oligoastrocytoma. The X01GB express both wild-type of EGFR and the mutant form, EGFRvIII. The X03AOA express only mutant form, EGFRvIII, whereas the X02GB does not express either wild-type EGFR or mutant form, EGFRvIII. The X02GB also express lower level of p53 and does not express phosphatase and tensin homolog. All patient-derived glioma cells (X01GB, X02GB and X03AOA) did not express O-6-methylguanine-DNA methyltransferase. Each patient provided written informed consent for tumor tissue.
U87MG, U373MG, X01GB, X02GB and X03AOA cells were resuspended in Dulbecco's modified Eagle's medium-F12 (Invitrogen) containing 20 ng/ml of EGF, bFGF and B27 (1:50) as sphere-forming condition, a stem-cell permissive medium. Spheres were collected after 5 to 7 days and protein was extracted for western blotting and kinase assay or dissociated with Accutase (Sigma, Seoul, Korea) for expansion. 58, 59 Cell sorting CD133-positive cells were sorted by a magnetic-activated cell sorting system. To this end, cells were washed with phosphate-buffered saline (PBS), dissociated to single cells using accutase (Sigma) and were stained with CD133-conjugated magnetic beads (Miltenyi Biotech) on ice for 30 min. Cells were then passed through a magnetic column, where CD133-positive cells were retained, whereas unlabeled cells were passed through the column. The CD133-positive cells were then eluted from the column after removal from the magnet. Quantitative analysis of CD133 and Nestin double-positive cells was performed by FACS using PE-conjugated CD133 antibody (BD, Seoul, Korea) and antibody for Nestin. Fluorescein isothiocyanate (Invitrogen) was used to detect Nestin-stained cells.
Quantification of cell death
Cell death was measured by FACS analysis using propidium iodide and annexin-V double staining. Cells were harvested by trypsinization, washed in PBS and then incubated in propidium iodide (50 ng/ml) and annexin-V for 5 min at room temperature. Cells (10 000 per sample) were analyzed on a FACSscan flow cytometer (Seoul, Korea), using Cell Quest software (Seoul, Korea).
Sphere-colony counting 
Lentiviral shRNA experiments
Lentiviral constructs encoding shRNA targeted to human JNK2 and nontargeted shRNA were purchased from OriGene Technologies, Inc. (Rockville, MD, USA; shRNA JNK2; Clone ID TRCN0000001013, nontargeting shRNA; Sigma-Aldrich SHC002, Seoul, Korea). 293T cells were seeded (3 Â 10 6 cells per ml) in 60-mm dish, and viral particles were generated by transfection as described previously. 60, 61 To standardize lentiviral transduction assays, viral titers were measured in a benchmark cell line, A549. For growth assays, titers corresponding to multiplicities of infection of 5 and 1 in A549 cells were employed. For JNK2 knockdown, cells were plated on day 0 at 1 Â 10 5 cells per ml in 60-mm dishs. Twentyfour hours after infection, cells were treated with 1 mg/ml puromycin to eliminate uninfected cells. Media was then replaced after 2 more days and cells were harvested for western blot or additional experiments.
RNA isolation and reverse-transcription PCR RNA was extracted using the RNeasy kit (QIAGEN, Valencia, CA, USA). RNA was treated with DNase I (Ambion, Austin, TX, USA) to eliminate any contaminating DNA. Reverse-transcription PCR reactions were performed with Super-Script III (Invitrogen) according to the manufacturer's instructions. Primer sequences are described as follows: CD133 (forward, 5 
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS. Following cell fixation, cells were incubated with the appropriate primary antibodies in a solution of PBS with 1% bovine serum albumin and 0.1% Triton X-100 at 4 1C overnight. Antibodies used were as follows: human anti-Nestin (rabbit polyclonal antibody, 1:200), Musashi-1 (rabbit polyclonal antibody, 1:200) and Tuj1 (mouse polyclonal antibody, 1:200). Stainings were visualized using anti-rabbit or anti-mouse Alexa Flour 488 (Molecular Probes, Seoul, Korea). Nuclei were counterstained using 4, 6-diamidino-2-phenylindole (Sigma). Stained cells were visualized with a fluorescence-microscope (Olympus IX71, Seoul, Korea).
PI3K kinase assay
Cell lysates (300 mg in 500 ml) were subjected to immunoprecipitation using anti-p85 antibodies (Upstate Biotechnology, Seoul, Korea). The precipitates were washed twice with PBS/1% NP40, followed by PBS, 0.1 mol/l Tris--HCl (pH 7.5) or 0.5 mol/l LiCl, and finally 25 mmol/l hydroxyethyl piperazineethanesulfonic acid (pH 7.5) or 100 mmol/l NaCl or 1 mmol/l EDTA. The precipitates were then resuspended in 50 ml of presonicated phosphatidylinositol substrate and incubated for 10 min at room temperature. Each sample was labeled with 10-Ci [ 32 P]ATP for 10 min at room temperature. Reactions were stopped by adding 100 ml of chloroform/methanol/HCl (50:100:1). Lipids were extracted with 200 ml chloroform and after mixing and centrifugation, the lower 'organic' phase was transferred to a new tube. The organic phase was washed once with 100 ml methanol:1 mol/l HCl (1:1), and the upper phase was discarded. Finally the lipid fraction was resuspended in 20 ml of chloroform and applied to a silica gel thin layer chromatography plate preimpregnated with 1% potassium oxalate. Phospholipids were resolved by thin layer chromatography in freshly prepared buffer---chloroform/methanol/ammonia/water (43:38:5:7) for 45 min in a closed glass chamber at room temperature. 62 Irradiation Cells were plated in 60 dishes and incubated at 37 1C under humidified 5% CO 2 in culture medium. Cells were exposed to g-rays using a 137Cs g-rays source (Atomic Energy of Canada, Ltd, Mississauga, Canada) at a dose rate of 3.81 Gy/min.
Monitoring of tumor growth
Tumorigenicity was determined by injecting U373 sphere-forming cell orthotopically into athymic BALB/c nu mice (KBT Oriental, Charles River Grade, Tosu, Saga, Japan). U373 sphere-forming cells (5000 in 5 ml) transfected with JNK2 shRNA (five mice) or nonspecific scramble shRNA (five mice) were injected through the burr hole in to the right striatum at the coordinates of 2.0 mm lateral to the midline, 3.0 mm in vertical, and anterior-posterior at the zero point to the bregma. The cell suspension was injected in 5 min and the syringe was raised 1 mm and left in place for 2 min to minimize diffusion of cells. Then, 3 and 6 weeks after cell transplantation, tumor growth was monitored by animal magnetic resonance imaging (Bruker, Seoul, Korea, BioSpin 70/20 USR, 7T). T2-weighted magnetic resonance imaging was performed in TR/TE ¼ 3500/ 70 ms with 1.0 mm slice thickness with 1-mm interval. The size of brain tumor were measured from the axial images and presented as an average diameter calculated by (length þ width of the tumor)/2. During the 6-week experimental procedure, condition of mice was monitored everyday and the survival rate was calculated, based on finding of dead mice (Kaplan --Meier survival curves).
This study was reviewed and approved by the Institutional Animal Care and Use Committee of Samsung Biomedical Research Institute, which is an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited facility and abide by the Institute of Laboratory Animal Resources guide.
Statistical analysis
All experimental data are reported as mean and the error bars represent the s.d. Statistical analysis was performed by the non-parametric Student's t-test.
